English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 46962/50828 (92%)
造訪人次 : 12388451      線上人數 : 1160
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    主頁登入上傳說明關於CCUR管理 到手機版


    請使用永久網址來引用或連結此文件: https://irlib.pccu.edu.tw/handle/987654321/48823


    題名: Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules
    作者: Ho, SY (Ho, Shu-Yi)
    Chen, PR (Chen, Pin-Rong)
    Chen, CH (Chen, Chia-Hung)
    Tsai, NM (Tsai, Nu-Man)
    Lin, YH (Lin, Yu-Hsin)
    Lin, CS (Lin, Chen-Si)
    Chuang, CH (Chuang, Cheng-Hsun)
    Huang, XF (Huang, Xiao-Fan)
    Chan, YL (Chan, Yi-Lin)
    Liu, YK (Liu, Yen-Ku)
    Chung, CH (Chung, Chen-Han)
    Weng, SL (Weng, Shun-Long)
    Liao, KW (Liao, Kuang-Wen)
    貢獻者: 生科系
    關鍵詞: LPPC
    Gene therapy
    Anti-angiogenesis
    RBDV
    VEGFR
    日期: 2020-04-09
    上傳時間: 2020-11-12 09:55:00 (UTC+8)
    摘要: Background The anti-angiogenic fusion protein RBDV-IgG1 Fc (RBDV), which comprises the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A), has shown antitumour effects by reducing angiogenesis in vivo. This study used the cationic lipoplex lipo-PEG-PEI-complex (LPPC) to simultaneously encapsulate both the RBDV targeting protein and the RBDV plasmid (pRBDV) without covalent bonds to assess VEGFR targeting gene therapy in mice with melanoma in vivo. Results LPPC protected the therapeutic transgene from degradation by DNase, and the LPPC/RBDV complexes could specifically target VEGFR-positive B16-F10 cells both in vitro and in vivo. With or without RBDV protein-targeting direction, the pRBDV-expressing RBDV proteins were expressed and reached a maximal concentration on the 7th day in the sera after transfection in vivo and significantly elicited growth suppression against B16-F10 melanoma but not IgG1 control proteins. In particular, LPPC/pRBDV/RBDV treatment with the targeting molecules dramatically inhibited B16-F10 tumour growth in vivo to provide better therapeutic efficacy than the treatments with gene therapy with IgG1 protein targeting or administration of a protein drug with RBDV. Conclusions The simultaneous combination of the LPPC complex with pRBDV gene therapy and RBDV protein targeting might be a potential tool to conveniently administer targeted gene therapy for cancer therapy.
    關聯: JOURNAL OF NANOBIOTECHNOLOGY 卷冊: 18 期: 1 文獻號碼: 58
    顯示於類別:[生命科學系] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML167檢視/開啟


    在CCUR中所有的資料項目都受到原著作權保護.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋